This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    MASCC Risk Index for Febrile Neutropenia

    Identifies patients at low risk for poor outcome with febrile neutropenia.

    INSTRUCTIONS

    Use in neutropenic patients (see ANC calculator) with fever at least 100.4°F (38ºC). Do not use in patients with acute leukemia undergoing induction chemotherapy or allogeneic hematopoietic stem cell transplant conditioning, per IDSA guidelines.

    When to Use
    Pearls/Pitfalls
    Why Use
    • Use at fever onset to assess risk of complications in febrile neutropenia for patients undergoing chemotherapy treatment.
    • Use after addressing immediate concerns to identify patients who may not need to be admitted to the hospital or could be discharged early.
    • Only applies to adult patients.
    • Validated as a dichotomous outcome; i.e., low risk versus not low risk. Obviously, patients who are “not low risk” have varying degrees of risk.

    Febrile neutropenia is a potentially life-threatening complication of chemotherapy, but some patients are at low risk for serious complications. The MASCC Risk Index is an internationally validated scoring system that identifies these low risk patients that can potentially be treated as an outpatient with early antibiotics.

    None or mild
    +5
    Moderate
    +3
    Severe
    0
    No
    +5
    Yes
    0
    No
    +4
    Yes
    0
    Solid tumor
    +4
    Hematologic, no prior fungal infection
    +4
    Hematologic, prior fungal infection
    0
    No
    +3
    Yes
    0
    Outpatient
    +3
    Inpatient
    0
    <60
    +2
    ≥60
    0

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Jean Klastersky

    About the Creator

    Jean Klastersky, MD, is a professor of medicine at the University of Brussels. He is also currently the chief of medicine services at the Institut Jules Bordet. Dr. Klastersky's research focuses on treatment and prognosis in neutropenic fever and novel therapies in cancer patients.

    To view Dr. Jean Klastersky's publications, visit PubMed

    Are you Dr. Jean Klastersky? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Content Contributors
    About the Creator
    Dr. Jean Klastersky
    Are you Dr. Jean Klastersky?
    Partner Content
    Content Contributors